Skip to content
Nonprofiteer
← ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS

Form 990 for tax year 2024

Filed by ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS.

Totals

Total revenue
$2,313,761
Total expenses
$2,437,532
Contributions and grants received
$0
Grants paid
$210,000
Program service revenue
$2,162,500
Investment income
$151,261
Other revenue
$0
Total assets, end of year
$3,293,943
Total liabilities, end of year
$47,623
Net assets or fund balances, end of year
$3,246,320
Program services expenses (Part IX)
not reported
Management and general expenses
not reported
Fundraising expenses
not reported
Program service expenses (Part III)
not reported

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 2a · Program service revenue: MEMBERSHIP DUES

    total $2,137,500 · related or exempt $2,137,500

  • 2b · Program service revenue: ACRO FORUM DUES

    total $25,000 · related or exempt $25,000

  • 3 · Investment income

    total $121,167 · excluded $121,167

  • 7a · Gross sales of assets other than inventory

    securities $1,431,000

  • 7b · Less cost or other basis and sales expenses

    securities $1,400,906

  • 7c · Gain or loss

    securities $30,094

  • 7d · Net gain or loss

    total $30,094 · excluded $30,094

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $210,000

  • 11a · Fees: management

    total $1,275,000

  • 11b · Fees: legal

    total $14,441

  • 11c · Fees: accounting

    total $41,623

  • 13 · Office expenses

    total $14,085

  • 16 · Occupancy

    total $37,440

  • 17 · Travel

    total $31,079

  • 19 · Conferences, conventions and meetings

    total $183,684

  • 22 · Depreciation, depletion and amortization

    total $10,649

  • 23 · Insurance

    total $4,113

  • 24a · Other expenses: MARKETING/COMMUNICATION

    total $201,222

  • 24b · Other expenses: FLEXIBLE RESOURCES

    total $190,119

  • 24c · Other expenses: D&I GRANTS PROGRAM

    total $64,242

  • 24d · Other expenses: MEMORIAL FUND: GLEN DE

    total $50,000

  • 24e · All other expenses

    total $109,835

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $413,725 · end of year $493,304

  • 2 · Savings and temporary cash investments

    beginning of year $354,452 · end of year $8,774

  • 4 · Accounts receivable

    beginning of year $75,000 · end of year $225,000

  • 9 · Prepaid expenses and deferred charges

    beginning of year $10,729 · end of year $4,250

  • 10a · Land, buildings and equipment: cost or other basis

    $63,650

  • 10b · Land, buildings and equipment: accumulated depreciation

    $39,449

  • 10c · Land, buildings and equipment, net

    beginning of year $34,850 · end of year $24,201

  • 11 · Investments: publicly traded securities

    beginning of year $2,537,693 · end of year $2,538,414

  • 17 · Accounts payable and accrued expenses

    beginning of year $55,128 · end of year $47,623

  • 27 · Net assets without donor restrictions

    beginning of year $3,371,321 · end of year $3,246,320

Mission and programs · 2024

Mission

ACRO AND ITS MEMBERS ADVOCATE ON A GLOBAL BASIS FOR SAFE, ETHICAL, HIGH-QUALITY MEDICAL RESEARCH SO PATIENTS CAN BENEFIT FROM THE DEVELOPMENT OF NEW TREATMENTS AND THERAPIES.

Activities or mission (Part I)

SEE SCHEDULE O.

  • THE ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS (ACRO) REPRESENTS THE WORLD'S LEADING CLINICAL RESEARCH ORGANIZATIONS AND CLINICAL TECHNOLOGY COMPANIES. ACRO'S MEMBERS PROVIDE SPECIALIZED SERVICES THAT ARE INTEGRAL TO THE DEVELOPMENT OF DRUGS, BIOLOGICS, AND MEDICAL DEVICES. ACRO ADVANCES CLINICAL OUTSOURCING TO IMPROVE THE QUALITY, EFFICIENCY, AND SAFETY OF BIOMEDICAL RESEARCH. ACRO'S PRIORITIES IN 2024 INCLUDED: 1. A US FOCUS ON REGULATORY ADVOCACY, SPECIFICALLY REPRESENTING CLINICAL RESEARCH AND CLINICAL TECHNOLOGY COMPANIES IN POLICY DISCUSSIONS WITH THE FDA. (CONTINUED IN SCHEDULE O) 2. EU ADVOCACY FOCUSED ON REPRESENTING THE INDUSTRY IN POLICY DISCUSSIONS WITH THE EUROPEAN COMMISSION, THE EUROPEAN MEDICINES AGENCY, AND UK AND OTHER EU MEMBER STATE REGULATORY BODIES.3. REPRESENTING MEMBER COMPANIES TO OTHER REGULATORS AND INDUSTRY STAKEHOLDERS SUCH AS CUSTOMERS.

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Peyton Howell

    CHAIR

    Total calculated
    $0
    Hours/week
    1

  • Cynthia Verst

    PAST CHAIR

    Total calculated
    $0
    Hours/week
    1

  • Jim Reilly

    VICE-CHAIR

    Total calculated
    $0
    Hours/week
    1

  • Mike Crowley

    SECRETARY

    Total calculated
    $0
    Hours/week
    1

  • Ari Feldman

    TREASURER

    Total calculated
    $0
    Hours/week
    1

  • Greg Licholai

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Lisa Moneymaker

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Joseph Schmidt

    BOARD MEMBER (Q1-Q3 2024)

    Total calculated
    $0
    Hours/week
    1

  • Karen Kaucic

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Seema Verma

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Catherine Gregor

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Gadi Saarony

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Jim Corrigan

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Cassandra Kennedy

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Douglas Peddicord

    EXECUTIVE DIRECTOR

    Total calculated
    $0
    Hours/week
    30

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.

Grants on this return

  • SMART CURES CLINICAL RESEARCH LLC

    $50,000

    TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE.

  • K2 MEDICAL RESEARCH LLC

    $40,000

    TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE.

  • PREFERRED PRIMARY CARE PHYSICIANS INC

    $40,000

    TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE.

  • NEBRASKA CANCER SPECIALISTS

    $20,000

    TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE.

  • BROOKLYN CLINICAL RESEARCH

    $20,000

    TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE.

  • SUPERIOR CLINICAL RESEARCH LLC

    $20,000

    TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE.

  • RANDOMIZE NOW

    $20,000

    TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE.

Provenance

Return type
form_990
Tax year
2024
Filed
6 June 2025
IRS schema version
2024v5.1
Source object
202541579349300739

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.